CSS LLC/IL - NEUROCRINE BIOSCIENCES INC ownership

NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 51 filers reported holding NEUROCRINE BIOSCIENCES INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
CSS LLC/IL ownership history of NEUROCRINE BIOSCIENCES INC
ValueSharesWeighting
Q4 2023$15,406,625
-33.6%
8,859,000
-43.4%
0.89%
-41.6%
Q3 2023$23,207,687
+16.3%
15,659,0000.0%1.52%
+23.3%
Q2 2023$19,952,839
+253.5%
15,659,000
+276.5%
1.24%
+231.1%
Q1 2023$5,643,651
+57.3%
4,159,000
+83.7%
0.37%
+83.7%
Q4 2022$3,587,738
+12.0%
2,264,0000.0%0.20%
+34.4%
Q3 2022$3,203,000
+51.5%
2,264,000
+42.7%
0.15%
+75.6%
Q2 2022$2,114,000
-92.6%
1,587,000
-92.7%
0.09%
-91.7%
Q1 2022$28,506,000
-11.5%
21,651,000
-15.6%
1.03%
-9.8%
Q4 2021$32,201,000
+14.1%
25,651,000
+21.5%
1.14%
-4.7%
Q3 2021$28,234,000
+350.2%
21,109,000
+366.3%
1.20%
+400.4%
Q4 2020$6,272,000
-81.3%
4,527,000
-81.4%
0.24%
-84.9%
Q3 2020$33,616,000
+155.9%
24,395,000
+209.0%
1.59%
+113.6%
Q2 2020$13,135,000
+50.2%
7,895,000
+15.4%
0.74%
+7.8%
Q1 2020$8,745,000
-2.6%
6,842,000
+17.0%
0.69%
+38.8%
Q4 2019$8,978,000
+17.3%
5,850,000
+5.1%
0.50%
+1.0%
Q3 2019$7,651,000
-32.7%
5,568,000
-35.3%
0.49%
-24.7%
Q2 2019$11,361,000
+143.0%
8,605,000
+149.1%
0.65%
+132.4%
Q1 2019$4,675,000
-43.7%
3,455,000
-50.3%
0.28%
-49.5%
Q4 2018$8,302,000
-67.5%
6,955,000
-53.5%
0.56%
-48.9%
Q3 2018$25,561,000
+97.3%
14,955,000
+67.2%
1.09%
+79.7%
Q2 2018$12,958,0008,944,0000.61%
Other shareholders
NEUROCRINE BIOSCIENCES INC shareholders Q2 2018
NameSharesValueWeighting ↓
SSI INVESTMENT MANAGEMENT LLC 7,440,000$10,058,0000.84%
SHENKMAN CAPITAL MANAGEMENT INC 4,121,000$5,579,0000.72%
Baker Brothers Advisors 53,270,000$71,994,0000.46%
LINDEN ADVISORS LP 11,675,000$15,814,0000.36%
ADVENT CAPITAL MANAGEMENT /DE/ 11,558,000$15,650,0000.34%
AQR Arbitrage LLC 20,000,000$27,077,0000.34%
CSS LLC/IL 3,455,000$4,675,0000.28%
RWC Asset Management LLP 4,000,000$5,396,0000.25%
MACKAY SHIELDS LLC 21,460,000$29,043,0000.21%
Calamos Advisors LLC 24,105,000$32,660,0000.20%
View complete list of NEUROCRINE BIOSCIENCES INC shareholders